Key facts
- LXO Group’s last known valuation is $353.2M (Nov 2020).
- Notable investors include Hayfin Capital Management, Stanley Capital.
- Status: Privately Held (backing).
Investors
2- ·The complete investor list — 2 names
- ·Watchlist + deal alerts for LXO Group
- ·The full record, as it builds
Funding rounds
No funding rounds for LXO Group are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About LXO Group
Manufacturer of pharmaceuticals intended for the needs of healthcare professionals and patients for medicines, medical devices, and cosmetics. The company markets a range of non-generic prescription drugs and over-the-counter drugs and focuses on drugs treating chronic diseases, enabling clients to meet the needs of healthcare professionals and patients for medicines, medical devices, and cosmetics.
- Sector
- Healthcare
- HQ
- Saint Cloud, France
- Founded
- 2015
- Employees
- 60
- Website
- lxogroup.com/
- Ownership
- Privately Held (backing)
LXO Group doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in LXO Group shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on LXO Group in its N-PORT filings yet. We sweep new filings monthly.